Drug Profile


Alternative Names: BIO-201

Latest Information Update: 04 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biophytis
  • Class Eye disorder therapies
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Age-related macular degeneration
  • Preclinical Dry age-related macular degeneration

Most Recent Events

  • 04 Apr 2017 Biophytis plans the phase II MACA-INT trial for Age-related macular degeneration
  • 22 Mar 2017 Preclinical trials in Dry age-related macular degeneration in France
  • 21 Mar 2017 Biophytis plans mid-stage clinical trials of BIO 201 for Dry age-related macular degeneration, in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top